Congenital disorders of glycosylation. Their diagnosis and treatment;Defectos congénitos de la glicosilación. Diagnóstico y tratamiento

Revista de Neurologia

Volumn 43, Issue SUPPL. 1, 2006, Pages

  Pérez Cerdá, Celia ^a   Ugarte, M ^a  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

Congenital disorders of glycosylation; Inborn errors of metabolism; N glycosylation; O glycosylation

Indexed keywords

FUCOSE; GLYCAN; GLYCOPROTEIN;

CELL GROWTH; CELL MIGRATION; CONFERENCE PAPER; CONGENITAL DISORDER OF GLYCOSYLATION; GENETIC DISORDER; HUMAN; LEUKOCYTE DISORDER; MUSCULAR DYSTROPHY; NERVE CELL; PROTEIN GLYCOSYLATION; SYMPTOMATOLOGY; ALGORITHM; GLYCOSYLATION; INBORN ERROR OF METABOLISM; REVIEW;

ALGORITHMS; GLYCOSYLATION; HUMANS; METABOLISM, INBORN ERRORS;

EID: 35348845955     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.43s01.2006386     Document Type: Conference Paper

References (80)

1. Lowe JB, Marth JD. A genetic approach to Mammalian glycan function. Annu Rev Biochem 2003; 72: 643-91.
2. Apweiler R, Hermjakob H, Sharon N. On the frequency of protein glycosylation, as deduced from analysis of the SWISS-PROT database. Biochim Biophys Acta 1999; 1473: 4-8.
3. Yarema KJ, Bertozzi CR. Characterizing glycosylation pathways. Genome Biol 2001; 2: reviews0004.1-0004.10.
4. Jaeken J. Vanderschueren-lodeweyckx M, Casaer P, Snoeck L, Corbeel L, Eggermont E, et al. Familial psychomotor retardation with marked- lyfluctuatingserum proteins, FSH and GH levels, partial TBG-deficiency, increased serum arylsulphatase A and increased CSF protein: a new syndrome? Pediatr Res 1980; 14: 179.
5. Marquardt T, Denecke J. Congenital disorders of glycosylation: review of their molecular bases, clinical presentations and specific therapies. Eur J Pediatr 2003; 162: 359-79.
6. Jaeken J. Komrower lecture. Congenital disorders of glycosylation (CDG): it's all in it! J Inherit Metab Dis 2003; 26: 99-118.
7. De Lonlay P, Seta N, Barrot S, Chabrol B, Drouin V, Gabriel BM, et al. A broad spectrum of clinical presentations in congenital disorders of glycosylation I: a series of 26 cases. J Med Genet 2001; 38: 14-9.
8. Briones P, Vilaseca MA, García-Silva MT, Pineda M, Colomer J, Ferrer I, et al. Congenital disorders of glycosylation (CDG) may be under-diagnosed when mimicking mitochondrial disease. Eur J Paediatr Neurol 2001; 5: 127-31.
9. Niehues R, Hasilik M, Alton G, Korner C, Schiebe-Sukumar M, Koch HG, et al. Carbohydrate-deficient glycoprotein syndrome type Ib. Phosphomannose isomerase deficiency and mannose therapy. J Clin Invest 1998; 101: 1414-20.
10. Jaeken J, Artigas J, Barone R, Fiumara A, De Koning TJ, Poll-The BT, et al. Phosphomannomutase deficiency is the main cause of carbohydrate-deficient glycoprotein syndrome with type I isoelectrofocusing pattern of serum sialotransferrins. J Inherit Metab Dis 1997; 20: 447-9.
11. Matthijs G, Schollen E, Pardon E, Veiga-Da-Cunha M, Jaeken J, Cassiman JJ, et al Mutations in PMM2, a phosphomannomutase gene on chromosome 16p13, in carbohydrate-deficient glycoprotein type I syndrome (Jaeken syndrome). Nat Genet 1997; 16: 88-92.
12. Albach C, Klein RA, Schmitz B. Do rodent and human brains have different N-glycosylation patterns? Biol Chem 2001; 382: 187-94.
13. Aronica E, Van Kempen AA, Van der Heide M, Poll-The BT, Van Slooten HJ, Troost D, et al. Congenital disorder of glycosylation type Ia: a clinicopathological report of a newborn infant with cerebellar pathology. Acta Neuropathol (Berl) 2005; 109: 433-42.
14. Colomé C, Ferrer I, Artuch R, Vilaseca MA, Pineda M, Briones P. Personal experience with the application of carbohydrate-deficient transferrin (CDT) assays to the detection of congenital disorders of glycosylation. Clin Chem Lab Med 2000; 38: 965-9.
15. Pérez-Cerdá C, Ecay MJ, Merinero B, Pérez B, Ugarte M. Ten new patients with congenital disorder of glycosylation (CDG) identified by selective screening. J Inherit Metab Dis 2004; 27: 187.
16. Helander A, Eriksson G, Stibler H, Jeppsson JO. Interference of transferrin isoform types with carbohydrate-deficient transferrin quantification in the identification of alcohol abuse. Clin Chem 2001; 47: 1225-33.
17. Stibler H, Holzbach U, Kristiansson B. Isoforms and levels of transferrin, antithrombin, alpha(1)-antitrypsin and thyroxine-binding globulin in 48 patients with carbohydrate-deficient glycoprotein syndrome type I. Scand J Clin Lab Invest 1998; 58: 55-61.
18. De Praeter CM, Gerwig GJ, Bause E, Nuytink LK, Vliegenthart JF, Breuer W, et al. A novel disorder caused by defective biosynthesis of N-linked oligosaccharides due to glucosidase I deficiency. Am J Hum Genet 2000; 66: 1744-56.
19. Lubke T, Marquardt T, Etzioni A, Hartmann E, Von Figura K, Korner C. Complementation cloning identifies CDG-IIc, a new type of congenital disorders of glycosylation, as a GDP-fucose transporter deficiency. Nat Genet 2001; 28: 73-6.
20. Martínez-Duncker I, Dupre T, Piller T, Piller V, Candelier JJ, Trichet C, et al. Genetic complementation reveals a novel human congenital disorder of glycosylation of type II, due to inactivation of the Golgi CMP-sialic acid transporter. Blood 2005; 105: 2671-6.
21. Fletcher JM, Matthijs G, Jaeken J, Van Schaftingen E, Nelson PV. Carbohydrate-deficient glycoprotein syndrome: beyond the screen. J Inherit Metab Dis 2000; 23: 396-8.
22. Artuch R, Ferrer I, Pineda J, Moreno J, Busquets C, Briones P, et al. Western blotting with diaminobenzidine detection for the diagnosis of congenital disorders of glycosylation. J Neurosci Methods 2003; 125: 167-71.
23. Fang J, Peters V, Korner C, Hoffmann GF. Improvement of CDG diagnosis by combined examination of several glycoproteins. J Inherit Metab Dis 2004; 27: 581-90.
24. Gravel P, Walzer C, Aubry C, Balant LP, Yersin B, Hochstrasser DF, et al. New alterations of serum glycoproteins in alcoholic and cirrhotic patients revealed by high resolution two dimensional gel electrophoresis. Biochem Biophys Res Commun 1996; 220: 79-85.
25. De Loos F, Huijben KM, Van der Kar NC, Monnens LA, Van den Heuvel LP, Groener JE, et al Hemolytic uremic syndrome attributable to Streptococcus pneumoniae: a novel cause for secondary N-glycan abnormalities. Clin Chem 2002; 48: 781-4.
26. Charlwood J, Clayton P, Keir G, Mian N, Winchester B. Defective galactosylation of serum transferrin in galactosemia. Glycobiology 1998; 8: 351-7.
27. Jaeken J, Pirard M, Adamowicz M, Pronicka E, Van Schaftingen E. Inhibition of phosphomannose isomerase by fructose 1-phosphate: an explanation for defective N-glycosylation in hereditary fructose intolerance. Pediatr Res 1996; 40: 764-6.
28. Rhim AD, Stoykova LI, Trindade AJ, Glick MC, Scanlin TF. Altered terminal glycosylation and the pathophysiology of CF lung disease. J Cyst Fibros 2004; 3 (Suppl 2): S95-6.
29. Grunewald S, Schollen E, Van Schaftingen E, Jaeken J, Matthijs G. High residual activity of PMM2 in patients' fibroblasts: possible pitfall in the diagnosis of CDG-Ia (phosphomannomutase deficiency). Am J Hum Genet 2001; 68: 347-54.
30. Panneerselvam K, Freeze HH. Mannose corrects altered N-glycosylation in carbohydrate-deficient glycoprotein syndrome fibroblasts. J Clin Invest 1996; 97: 1478-87.
31. Butler M, Quelhas D, Critchley AJ, Carchon H, Hebestreit HF, Hibbert RG, et al. Detailed glycan analysis of serum glycoproteins of patients with congenital disorders of glycosylation indicates the specific defective glycan processing step and provides an insight into pathogenesis. Glycobiology 2003; 13: 601-22.
32. Mills PB, Mills K, Mian N, Winchester BG, Clayton PT. Mass spectrometric analysis of glycans in elucidating the pathogenesis of CDG type IIx. J Inherit Metab Dis 2003; 26: 119-34.
33. Wada Y. Mass spectrometry for congenital disorders of glycosylation, CDG. J Chromatogr B Analyt Technol Biomed Life Sci 2006; 838: 3-8.
34. Matthijs G, Schollen E, Bjursell C, Erlandson A, Freeze H, Imtiaz F, et al. Mutations in PMM2 that cause congenital disorders of glycosylation, type Ia (CDG-Ia). Hum Mutat 2000; 16: 386-94.
35. Le Bizec C, Vuillaumier-Barrot S, Barnier A, Dupre T, Durand G, Seta N. A new insight into PMM2 mutations in the French population. Hum Mutat 2005; 25: 504-5.
36. Pérez-Cerdá C, Pérez B, Leal F, Ecay MJ, Desviat LR, Merinero B, et al. PMM2 mutation analysis in patients with type 1 sialotransferrin pattern. Family studies and prenatal diagnosis. J Inherit Metab Dis 2005; 28: 198.
37. Vuillaumier-Barrot S, Le Bizec C, De Lonlay P, Madinier-Chappat N, Barnier A, Dupre T, et al. PMM2 intronic branch-site mutations in CDG-Ia. Mol Genet Metab 2006; 87: 337-40.
38. Briones P, Vilaseca MA, Schollen E, Ferrer I, Maties M, Busquets C, et al. Biochemical and molecular studies in 26 Spanish patients with congenital disorder of glycosylation type Ia. J Inherit Metab Dis 2002; 25: 635-46.
39. Schollen E, Kjaergaard S, Legius E, Schwartz M, Matthijs G. Lack of Hardy-Weinberg equilibrium for the most prevalent PMM2 mutation in CDG-Ia (congenital disorders of glycosylation type Ia). Eur J Hum Genet 2000; 8: 367-71.
40. Pirard M, Matthijs G, Heykants L, Schollen E, Grunewald S, Jaeken J, et al. Effect of mutations found in carbohydrate-deficient glycoprotein syndrome type IA on the activity of phosphomannomutase 2. FEBS Lett 1999; 452: 319-22.
41. Clayton P, Winchester B, Di Tomaso E, Young E, Keir G, Rodeck C. Carbohydrate-deficient glycoprotein syndrome: normal glycosylation in the fetus. Lancet 1993; 341: 956.
42. Matthijs G, Schollen E, Cassiman JJ, Cormier-Daire V, Jaeken J, Van Schaftingen E. Prenatal diagnosis in CDG1 families: beware of heterogeneity. Eur J Hum Genet 1998; 6: 99-104.
43. Matthijs G, Schollen E, Van Schaftingen E. The prenatal diagnosis of congenital disorders of glycosylation (CDG). Prenat Diagn 2004; 24: 114-6.
44. Westphal V, Kjaergaard S, Davis JA, Peterson SM, Skovby F, Freeze HH. Genetic and metabolic analysis of the first adult with congenital disorder of glycosylation type Ib: long-term outcome and effects of mannose supplementation. Mol Genet Metab 2001; 73: 77-85.
45. Marquardt T, Luhn K, Srikrishna G, Freeze HH, Harms E, Vestweber D. Correction of leukocyte adhesion deficiency type II with oral fucose. Blood 1999; 94: 3976-85.
46. Etzioni A, Sturla L, Antonellis A, Green ED, Gershoni-Baruch R, Berninsone PM, et al. Leukocyte adhesion deficiency (LAD) type II/carbohydrate deficient glycoprotein (CDG) IIc founder effect and genotype/ phenotype correlation. Am J Med Genet 2002; 110: 131-5.
47. Mayatepek E, Kohlmuller D. Mannose supplementation in carbohydrate-deficient glycoprotein syndrome type I and phosphomannomutase deficiency. Eur J Pediatr 1998; 157: 605-6.
48. Eklund EA, Merbouh N, Ichikawa M, Nishikawa A, Clima JM, Dorman JA, et al. Hydrophobic Man-1-P derivatives correct abnormal glycosylation in type I congenital disorder of glycosylation fibroblasts. Glycobiology 2005; 15: 1084-93.
49. Okajima T, Fukumoto S, Furukawa K, Urano T. Molecular basis for the progeroid variant of Ehlers-Danlos syndrome. Identification and characterization of two mutations in galactosyltransferase I gene. J Biol Chem 1999; 274: 28841-4.
50. Wuyts W, Van Hul W. Molecular basis of multiple exostoses: mutations in the EXT1 and EXT2 genes. Hum Mutat 2000; 15: 220-7.
51. Muntoni F, Brockington M, Blake DJ, Torelli S, Brown SC. Defective glycosylation in muscular dystrophy. Lancet 2002; 360: 1419-21.
52. Topaz O, Shurman DL, Bergman R, Indelman M, Ratajczak P, Mizrachi M, et al. Mutations in GALNT3, encoding a protein involved in O-linked glycosylation, cause familial tumoral calcinosis. Nat Genet 2004; 36: 579-81.
53. Wopereis S, Lefeber DJ, Morava E, Wevers RA. Mechanisms in protein O-glycan biosynthesis and clinical and molecular aspects of protein O-glycan biosynthesis defects: a review. Clin Chem 2006; 52: 574-600.
54. Whyte JR, Munro S. The Sec34/35 Golgi transport complex is related to the exocyst, defining a family of complexes involved in multiple steps of membrane traffic. Dev Cell 2001; 1: 527-37.
55. Kingsley DM, Kozarsky KF, Segal M, Krieger M. Three types of low density lipoprotein receptor-deficient mutant have pleiotropic defects in the synthesis of N-linked, O-linked, and lipid-linked carbohydrate chains. J Cell Biol 1986; 102: 1576-85.
56. Wu X, Steet RA, Bohorov O, Bakker J, Newel J, Krieger M, et al. Mutation of the COG complex subunit gene COG7 causes a lethal congenital disorder. Nat Med 2004; 10: 518-23.
57. Foulquier F, Vasile E, Schollen E, Callewaert N, Raemaekers T, Quelhas D, et al. Conserved oligomeric Golgi complex subunit 1 deficiency reveals a previously uncharacterized congenital disorder of glycosylation type II. Proc Natl Acad Sci U S A 2006; 103: 3764-9.
58. Wopereis S, Morava E, Grunewald S, Mills PB, Winchester BG, Clayton P, et al. A combined defect in the biosynthesis of N- and O-glycans in patients with cutis laxa and neurological involvement: the biochemical characteristics. Biochim Biophys Acta 2005; 1741: 156-64.
59. Albahri Z, Marklova E, Dedek P, Hojdikova H, Fiedler Z, Lefeber D, et al. CDG: a new case of a combined defect in the biosynthesis of N- and O-glycans. Eur J Pediatr 2006; 165: 203-4.
60. Grunewald S, Imbach T, Huijben K, Rubio-Gozalbo ME, Verrips A, De Klerk JB, et al. Clinical and biochemical characteristics of congenital disorder of glycosylation type Ic, the first recognized endoplasmic reticulum defect in N-glycan synthesis. Ann Neurol 2000; 47: 776-81.
61. Korner C, Knauer R, Stephani U, Marquardt T, Lehle L, Von Figura K. Carbohydrate deficient glycoprotein syndrome type IV: deficiency of dolichyl-P-Man:Man(5)GlcNAc(2)-PP-dolichyl mannosyltransferase. EMBO J 1999; 18: 6816-22.
62. Imbach T, Schenk B, Schollen E, Burda P, Stutz A, Grunewald S, et al. Deficiency of dolichol-phosphate-mannose synthase-1 causes congenital disorder of glycosylation type Ie. J Clin Invest 2000; 105: 233-9.
63. García-Silva MT, Matthijs G, Schollen E, Cabrera JC, Sánchez del Pozo J, Martí-Herreros M, et al. Congenital disorder of glycosylation (CDG) type Ie. A new patient. J Inherit Metab Dis 2004; 27: 591-600.
64. Kranz C, Denecke J, Lehrman MA, Ray S, Kienz P, Kreissel G, et al. A mutation in the human MPDU1 gene causes congenital disorder of glycosylation type If (CDG-If). J Clin Invest 2001; 108: 1613-9.
65. Di Rocco M, Hennet T, Grubenmann CE, Pagliardini S, Allegri AE, Frank CG, et al. Congenital disorder of glycosylation (CDG) Ig: report on a patient and review of the literature. J Inherit Metab Dis 2005; 28: 1162-4.
66. Eklund EA, Sun L, Westphal V, Northrop JL, Freeze HH, Scaglia F. Congenital disorder of glycosylation (CDG)-Ih patient with a severe hepato-intestinal phenotype and evolving central nervous system pathology. J Pediatr 2005; 147: 847-50.
67. Thiel C, Schwaez M, Peng J, Grzmil M, Hasilik M, Braulke T, et al. A new type of congenital disorders of glycosylation (CDG-Ii) provides new insights into the early steps of dolichol-linked oligosaccharide biosynthesis. J Biol Chem 2003; 278: 22498-505.
68. Wu X, Rush JS, Karaoglu D, Krasnewich D, Lubinsky MS, Waechter CJ, et al. Deficiency of UDP-GlcNAc:Dolichol Phosphate N-Acetylglucosamine-1 Phosphate Transferase (DPAGT1) causes a novel congenital disorder of glycosylation type Ij. Hum Mutat 2003; 22: 144-50.
69. Grubenmann CE, Frank CG, Hulsmeier AJ, Shollen E, Matthijs G, Mayatepek E, et al. Deficiency of the first mannosylation step in the N-glycosylation pathway causes congenital disorder of glycosylation type Ik. Hum Mol Genet 2004; 13: 535-42.
70. Frank CG, Grubenmann CE, Eyaid W, Berger EG, Aebi M, Hennet T. Identification and functional analysis of a defect in the human ALG9 gene: definition of congenital disorder of glycosylation type IL. Am J Hum Genet 2004; 75: 146-50.
71. Tan J, Dunn J, Jaeken J, Schachter H. Mutations in the MGAT2 gene controlling complex N-glycan synthesis cause carbohydrate-deficient glycoprotein syndrome type II, an autosomal recessive disease with defective brain development. Am J Hum Genet 1996; 59: 810-7.
72. Marquardt T, Brune T, Luhn K, Zimmer KP, Korner C, Fabritz L, et al. Leukocyte adhesion deficiency II syndrome, a generalized defect in fucose metabolism. J Pediatr 1999; 134: 681-8.
73. Hansske B, Thiel C, Lubke T, Hasilik M, Honning S, Peters V, et al. Deficiency of UDP-galactose: N-acetylglucosamine beta-1,4-galactosyltransferase I causes the congenital disorder of glycosylation type IId. J Clin Invest 2002; 109: 725-33.
74. Beltrán-Valero de Bernabé D, Currier S, Steinbrecher A, Celli J, Van Beusekom E, Van der Zwaag B, et al. Mutations in the O-mannosyltransferase gene POMT1 give rise to the severe neuronal migration disorder Walker-Warburg syndrome. Am J Hum Genet 2002; 71: 1033-43.
75. Kano H, Kobayashi K, Herrmann R, Tachikawa M, Manya H, Nishino I, et al. Deficiency of alpha-dystroglycan in muscle-eye-brain disease. Biochem Biophys Res Commun 2002; 291: 1283-6.
76. Hayashi YK, Ogawa M, Tagawa K, Noguchi S, Ishihara T, Nonaka I, et al. Selective deficiency of alpha-dystroglycan in Fukuyama-type congenital muscular dystrophy. Neurology 2001; 57: 115-21.
77. Brockington M, Blake DJ, Prandini P, Brown SC, Torelli S, Benson MA, et al. Mutations in the fukutin-related protein gene (FKRP) cause a form of congenital muscular dystrophy with secondary laminin alpha2 deficiency and abnormal glycosylation of alpha-dystroglycan. Am J Hum Genet 2001; 69: 1198-209.
78. Brockington M, Yuva Y, Prandini P, Brown SC, Torelli S, Benson MA, et al. Mutations in the fukutin-related protein gene (FKRP) identify limb girdle muscular dystrophy 2I as a milder allelic variant of congenital muscular dystrophy MDC1C. Hum Mol Genet 2001; 10: 2851-9.
79. Longman C, Brockington M, Torelli S, Jiménez-Mallebrera C, Kennedy C, Khalil N, et al. Mutations in the human LARGE gene cause MDC1D, a novel form of congenital muscular dystrophy with severe mental retardation and abnormal glycosylation of alpha-dystroglycan. Hum Mol Genet 2003; 12: 2853-61.
80. Spaapen LJ, Bakker JA, Van der Meer SB, Sijstermans HJ, Steet RA, Wevers RA, et al. Clinical and biochemical presentation of siblings with COG-7 deficiency, a lethal multiple O- and N-glycosylation disorder. J Inherit Metab Dis 2005; 28: 707-14.